OncoMatch/Clinical Trials/NCT05970666
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Is NCT05970666 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TACE with adebrelimab and bevacizumab for adebrelimab.
Treatment: TACE with adebrelimab and bevacizumab — To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage ⅡA, ⅡB, ⅢA, ⅢB (CNLC)
The CNLC stage is Ⅱa-Ⅲb stage
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: targeted therapy
have received targeted therapy and other PD-1 / PD-L1 inhibitor therapy
Cannot have received: PD-1/PD-L1 inhibitor
have received targeted therapy and other PD-1 / PD-L1 inhibitor therapy
Cannot have received: systemic therapy
Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment
Lab requirements
Blood counts
Hemoglobin ≥90g/L; WBC ≥3x10^9/L; ANC ≥1.5x10^9/L; Platelet ≥80x10^9/L
Kidney function
Serum creatinine ≤1.5x ULN
Liver function
Child-Pugh grade A or B (5-7 points); Bilirubin <1.5x ULN; ALT and AST <5x ULN
Cardiac function
No severe cardiovascular disease; LVEF ≥50%; no poorly controlled arrhythmia (QTc <450 ms men, <470 ms women)
The Child-Pugh grade of liver function is A grade or B grade (5-7 points); Bilirubin (BIL) <1.5 times the upper limit of normal value (ULN); Glutamic gamma aminotransferase (ALT) and glutamate aminotransferase AST <5 ULN; Serum creatinine (Cr)≤1.5ULN; Hemoglobin (HB), 90g / L, White blood cell count (WBC) 3109 / L Absolute neutrophil count (ANC) 1.5109 / L, Platelet (PLT) 80109 / L; Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in QTc men and 470 ms in women); cardiac dysfunction by NYHA, or cardiac ultrasound indicating left ventricular ejection fraction (LVEF) <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify